» Articles » PMID: 10691920

Interferons and Interferon (IFN)-inducible Protein 10 During Highly Active Anti-retroviral Therapy (HAART)-possible Immunosuppressive Role of IFN-alpha in HIV Infection

Overview
Date 2000 Feb 26
PMID 10691920
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Interferons play an important, but incompletely understood role in HIV-related disease. We investigated the effect of HAART on plasma levels of IFN-alpha, IFN-gamma, neopterin and interferon-inducible protein 10 (IP-10) in 41 HIV-infected patients during 78 weeks of therapy. At baseline HIV-infected patients had raised levels of both IP-10 and IFN-alpha compared with healthy controls (n = 19), with particularly high levels in advanced disease. HAART induced a marked decrease in levels of both IFN-alpha, neopterin and IP-10, though not to normal concentrations. In contrast, IFN-gamma levels were low throughout the study, and not different from controls. While neopterin and IP-10 remained significantly decreased compared with baseline levels throughout the study, IFN-alpha levels returned to baseline at the end of the study. Persistently high IP-10 and IFN-alpha levels were associated with immunological treatment failure and even high baseline levels of IFN-alpha appeared to predict immunological relapse. Furthermore, we found a markedly suppressive effect of exogenously added IFN-alpha on phytohaemagglutinin-stimulated lymphocyte proliferation in both patients and controls, and this suppressive effect seemed not to involve enhanced lymphocyte apoptosis. Our findings suggest a pathogenic role of IFN-alpha in HIV infection, which may be a potential target for immunomodulating therapy in combination with HAART.

Citing Articles

Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllers.

Poveda E, Fitzgerald W, Alonso-Dominguez J, Aguayo-Arjona J, Marino A, Alvarez H Front Immunol. 2024; 15:1446730.

PMID: 39267749 PMC: 11390527. DOI: 10.3389/fimmu.2024.1446730.


CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.

Elemam N, Talaat I, Maghazachi A Viruses. 2022; 14(11).

PMID: 36366543 PMC: 9696077. DOI: 10.3390/v14112445.


Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.

Russo E, Nannini G, Sterrantino G, Kiros S, Di Pilato V, Coppi M World J Gastroenterol. 2022; 28(6):635-652.

PMID: 35317423 PMC: 8900548. DOI: 10.3748/wjg.v28.i6.635.


Interferon-β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation.

Fueyo-Gonzalez F, McGinty M, Ningoo M, Anderson L, Cantarelli C, Angeletti A Immunity. 2022; 55(3):459-474.e7.

PMID: 35148827 PMC: 8917088. DOI: 10.1016/j.immuni.2022.01.011.


Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features.

Bartsch Y, Loos C, Rossignol E, Fajnzylber J, Yuan D, Avihingsanon A mBio. 2021; 12(2).

PMID: 33688003 PMC: 8092214. DOI: 10.1128/mBio.00170-21.


References
1.
Cousens L, Orange J, Su H, Biron C . Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. Proc Natl Acad Sci U S A. 1997; 94(2):634-9. PMC: 19565. DOI: 10.1073/pnas.94.2.634. View

2.
Aman M, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky W . Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood. 1996; 87(11):4731-6. View

3.
Neville L, Mathiak G, Bagasra O . The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1998; 8(3):207-19. DOI: 10.1016/s1359-6101(97)00015-4. View

4.
Biron C . Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol. 1998; 10(5):383-90. DOI: 10.1006/smim.1998.0138. View

5.
Valdez H, Lederman M . Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997; :187-228. View